The Marth laboratory is incorporating nanotechnologies, microfluidics, and microarray platforms to develop novel capabilities in biomedical research that can improve disease diagnosis and generate more effective nanomedicine-based therapeutics. Technology projects include the development of high-throughput sensors that simultaneously interrogate the four main types of cellular components, the nucleic acids, proteins, lipids, and glycans, and which together govern health and disease. Research projects span molecular and cellular biology, as well as animal physiology, and focus on diabetes, autoimmune diseases, cancer, infectious disease, and neurological dysfunction. Research in the Marth laboratory has discovered unexpected pathogenic mechanisms responsible for Type 2 diabetes, systemic lupus erythematosus, the lethal complications of sepsis, and more recently epilepsy. These findings indicate that there exist biomarkers and causes of disease for which no relevant diagnostics or therapeutics presently exist. The laboratory research program is based on the premise that a more rigorous and holistic understanding of the pathophysiologic and cellular origins of disease will illuminate the most effective approaches to achieve prevention, treatment, and cure.